Upsher Smith Laboratories, Inc.

Clexio Biosciences Ltd.

Cima Labs Inc.

Other

Athena Neurosciences, Inc.

Victoria Ann O'Neill

Derek V Moe

Manuel A Vega Zepeda

Dinesh K Haswani

Kenneth L Evenstad

Randal A Seburg

Christian F Wertz

Stephen M Berge

James S Jensen

Gloria A Rood

Sean B Mahoney

Kuldip R Malhotra

Thomas R Gorham

Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

Immediate release abuse-deterrent granulated dosage forms

Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.

Dermatological compositions and methods

Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.

Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug

Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug

The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).

Opioid-containing oral pharmaceutical compositions and methods

Growing community of inventors

Wayzata, MN, United States of America

Victoria Ann O'Neill